Phase 1b and Dose-Expansion Study of GSK3326595, a PRMT5 Inhibitor as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cancers
{{output}}
Background: Protein arginine methyltransferase 5 (PRMT5) inhibition often leads to a decrease in cell growth and survival in cancer cell lines. GSK3326595 is a first-generation PRMT5 inhibitor. ... ...
